You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
McKesson
Harvard Business School
Boehringer Ingelheim
Colorcon

Last Updated: September 21, 2020

DrugPatentWatch Database Preview

Patent: 9,796,754

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,796,754
Title:Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
Abstract: Disclosed herein are non-natural amino acids and dolastatin analogs that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The dolastatin analogs can include a wide range of possible functionalities, but typically have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid dolastatin analogs and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology use.
Inventor(s): Miao; Zhenwei (San Diego, CA), Atkinson; Kyle (Golden, CO), Biroc; Sandra (Alameda, CA), Buss; Timothy (Carlsbad, CA), Neal; Melissa (Vista, CA), Kraynov; Vadim (San Diego, CA), Marsden; Robin (San Diego, CA), Pinkstaff; Jason (San Rafael, CA), Skidmore; Lillian (San Diego, CA), Sun; Ying (San Diego, CA), Szydlik; Agnieszka (San Francisco, CA), Lopez De Valenta; Delia Ianina (Poway, CA)
Assignee: Ambrx, Inc. (La Jolla, CA)
Application Number:14/122,672
Patent Claims:see list of patent claims

Details for Patent 9,796,754

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial Ambrx, Inc. (La Jolla, CA) 2031-05-27 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Medtronic
Johnson and Johnson
McKinsey
Harvard Business School
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.